医学
髓系白血病
内科学
肿瘤科
白血病
化疗
骨髓
急性白血病
髓样
癌症研究
诱导化疗
阿糖胞苷
血小板
作者
Etsuko Yamazaki,Heiwa Kanamori,Megumi Itabashi,Eriko Ogusa,Ayumi Numata,Wataru Yamamoto,Satomi Ito,Takayoshi Tachibana,Maki Hagihara,Kenji Matsumoto,Hideyuki Koharazawa,Jun Taguchi,Naoto Tomita,Katsumichi Fujimaki,Hiroyuki Fujita,Shin Fujisawa,Koji Ogawa,Yoshiaki Ishigatsubo
标识
DOI:10.1080/10428194.2016.1190969
摘要
AbstractWe verified the association between standard clinical and laboratory variables and the risk of relapse in acute myeloid leukemia (AML), which led us to retrospectively examine the effect of regeneration of hematopoiesis in patients with newly diagnosed AML. We used data from 230 patients who obtained remission after cytarabine-based induction chemotherapy. Platelet counts ≥500 × 109/L and hemoglobin levels ≥9 g/dL on day 28 after treatment initiation were significantly associated with relapse-free survival (RFS) rate, conferring respective multivariate risk ratios of 0.38 (95% CI: 0.18–0.79) and 0.60 (95% CI: 0.40–0.89) for the occurrence of relapse or death. No disease relapse occurred in core binding factor leukemia patients whose platelet counts recovered ≥500 × 109/L at 28 days after therapy initiation. We conclude that regeneration of hematopoiesis, especially platelet hyper-recovery, after induction chemotherapy is a significant predictor of RFS in patients with AML.
科研通智能强力驱动
Strongly Powered by AbleSci AI